Clinical outcomes of standard triple therapy plus probiotics or concomitant therapy for Helicobacter pylori infection

Jae Hyun Jung, In Kuk Cho, Chang Hee Lee, Gwan Gyu Song, Ji Hyun Lim

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background/Aims: The efficacy of standard triple therapy (STT) in treating Helicobacter pylori infection has decreased. Many investigators have attempted to increase the eradication rate. We investigated the outcomes of concomitant therapy (CT) and STT combined with probiotics (STP) as a first-line treatment for H. pylori infection. Methods: We reviewed the medical records of 361 patients who received either STP (n=286) or CT (n=75). The STP group received STT combined with a probiotic preparation for 1 week. The CT group received STT and metronidazole for 1 week. Results: The intention-to-treat and per-protocol eradication rates were 83.6% (95% confidence interval [CI], 79.0 to 87.7) and 87.1% (95% CI, 81.2 to 89.7) in the STP group and 86.7% (95% CI, 78.7 to 93.3) and 91.4% (95% CI, 83.6 to 97.1) in the CT group (p=0.512 and p=0.324), respectively. The frequency of adverse effects was higher in the CT group (28.2%) than in the STP group (12.8%) (p=0.002). Conclusions: STP and CT are encouragingly efficacious as first-line treatments for H. pylori infection. Therefore, adding probiotics to STT may be a feasible option to avoid side effects. (Gut Liver 2018;12:165-172).

Original languageEnglish
Pages (from-to)165-172
Number of pages8
JournalGut and Liver
Volume12
Issue number2
DOIs
Publication statusPublished - 2018 Mar 1

Keywords

  • Helicobacter pylori
  • Metronidazole
  • Probiotics

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Clinical outcomes of standard triple therapy plus probiotics or concomitant therapy for Helicobacter pylori infection'. Together they form a unique fingerprint.

  • Cite this